Fesoterodine
 |
|
|---|---|
| Systematic (IUPAC) name | |
| [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate | |
| Clinical data | |
| Trade names | Toviaz |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a609021 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | C (US) |
| Legal status | ℞ Prescription only |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 52% (active metabolite) |
| Protein binding | 50% (active metabolite) |
| Metabolism | Hepatic (CYP2D6- and 3A4-mediated) |
| Half-life | 7–8 hours (active metabolite) |
| Excretion | Renal (70%) and fecal (7%) |
| Identifiers | |
| CAS number | 286930-03-8  |
| ATC code | G04BD11 |
| PubChem | CID 6918558 |
| DrugBank | DB06702 |
| ChemSpider | 5293755  |
| UNII | 621G617227 |
| KEGG | D07226 |
| ChEMBL | CHEMBL1201764 |
| Chemical data | |
| Formula | C26H37NO3 |
| Mol. mass | 411.278 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007[2] and was approved by the US Food and Drug Administration on October 31, 2008.[3]
Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.
[edit] Efficacy
In two large, 12-week, randomized, double-blind multicentre Phase III trials, oral fesoterodine 4 or 8mg once daily improved the symptoms of OAB significantly more than placebo.[4]
[edit] References
- ^ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. http://www.medicalnewstoday.com/articles/41688.php.
- ^ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. http://www.emea.europa.eu/humandocs/Humans/EPAR/toviaz/toviaz.htm.
- ^ "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc.. 2008-10-31. http://www.drugs.com/newdrugs/pfizer-s-toviaz-fesoterodine-fumarate-receives-fda-approval-overactive-bladder-1167.html. Retrieved 2008-11-06.
- ^ McKeage K, Keating GM.[1].Drugs 2009; 69(6):731-738.doi: 10.2165/00003495-200969060-00006.
|
||||||||||||||||
 |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
